The aim of the present study was to evaluate in patients with acute lymphoblastic leukemia (ALL), the oxidative status and antioxidant defense and its involvement in the relapse of ALL. The plasmatic levels of malondialdehyde, advanced oxidation of protein products and reduced glutathione (GSH), and the plasmatic activities of catalase, superoxide dismutase (SOD), and glutathione peroxidase were determined in 34 patients who were newly diagnosed with ALL and compared with 92 healthy individuals. The plasmatic concentrations of malondialdehyde and advanced oxidation of protein products were higher in ALL patients than in controls and increased during chemotherapy. A decrease in glutathione peroxidase activity and an increase in catalase and SOD activities and GSH plasma levels were observed in ALL patients, as compared with sex-matched controls. Moreover, SOD activity and GSH levels were significantly correlated with the relapse of ALL patients. These data suggest the involvement of oxidative stress in acute lymphoid leukemias and leukemic relapse.
A cute lymphoblastic leukemia (ALL) is a malignant neoplasm of lymphocytes characterized by uncontrolled proliferation and maturation arrest of lymphoid progenitor cells in bone marrow, resulting in an excess of malignant cells. 1 This disease is more common in children, who represent 80% of all leukemia cases. It is a curable disease with an expected long-term survival rate of at least 70% when treated with modern therapeutic regimens. A common chemotherapy treatment for ALL begins with induction chemotherapy, in which a combination of drugs is used to destroy as many leukemia cells as possible and bring blood counts to normal. 2 This is followed by consolidation chemotherapy to destroy any remaining leukemia cells that cannot be seen in the blood or bone marrow. Patients with ALL may also receive maintenance chemotherapy.
Nevertheless, despite this intensive chemotherapy, relapse represents the main cause for treatment failure. 3 Several approaches have been proposed to help predict the poor disease-free and poor overall survival rates for children with ALL. 4, 5 Extensive evidence has shown that disturbances of oxidative stress metabolism are a common feature of transformed tumor cells. 6 Oxidative stress has been characterized by an imbalance between the production of reactive oxygen species (ROS) and a biological system's ability to repair oxidative damage or to neutralize the reactive intermediates including peroxides and free radicals. 7 Enhanced levels of ROS can cause damage to biomolecules such as lipids, proteins, and DNA, leading to cellular dysfunction and cell death. The effect of reactive species is balanced by the antioxidant action of nonenzymatic antioxidants as well as by antioxidant enzymes. 8 Conflicting data have been reported on the oxidative status in ALL patients. Moreover, information about the levels of oxidative damage and antioxidant defenses in patient newly diagnosed with ALL as compared with those in the different stages of treatment are rare. 9 This study was performed in patients with ALL to evaluate (i) the oxidative status, through the measurement of lipid peroxidation and the levels of advanced oxidation of protein products (AOPPs), (ii) the antioxidant defense through the verification of main enzymatic antioxidant defenses (superoxide dismutase [SOD] , catalase [CAT] , and glutathione peroxidase [GPx] ) and nonenzymatic antioxidants (thiol antioxidants), and (iii) the involvement of the oxidative status in the relapse of ALL.
METHODS

Participants
The sample consisted of 34 patients (22 male and 12 female) newly diagnosed with ALL, who were prospectively recruited from the hematology department of Hedi Chaker Hospital University in Sfax (south of Tunisia) from January 2013 to December 2014.
The control group consisted of 92 sex-matched healthy control individuals enrolled from the general population. Exclusion criteria of this group were (i) age above 30 years, (ii) a history of alcoholism, smoking, and diseases that induce oxidative stress such as diabetes mellitus, respiratory diseases, cardiovascular diseases etc., and (iii) taking any medication or antioxidant supplements.
Patients were diagnosed and treated according to the EORTC-CLG 58951 protocol, a Berlin-Frankfurt-Munster-like trial. The treatment involves a sequential phase of induction, consolidation, interval, intensification, and maintenance therapy. 10 Patient data were collected from the hospital records and extracted information such as age, sex, subtype of ALL (B-cell ALL or T-cell ALL), biological disorder in blood (complete blood count, fibrinogen levels, acid uric levels, liver, and renal function tests), and blast count in marrow. Information about the risk of relapse of ALL within 2 years from initial diagnosis was also collected for each patient.
This study was conducted in accordance with the Helsinki Declaration and informed consent was obtained from all the persons participating in this study.
Plasma Samples
Blood was collected in tubes containing ethylene diaminetetraacetic acid. Plasma was separated from red cells by centrifugation at 3000 rpm for 15 minutes. Plasma was immediately aliquoted and stored at À 801C until analysis.
For each ALL patient included in this study, blood samples were collected at diagnosis just before chemotherapy, and then during successive treatment phases: induction, consolidation, interval, and maintenance therapy.
Protein Rate Determination
Total protein concentration was determined by the Bradford method, 11 calibrated with bovine serum albumin.
Measurement of Malondialdehyde (MDA)
Lipid peroxidation was assessed by thiobarbituric acid (TBA) reactive substances by measuring plasma levels of MDA, using the method described by Buege and Aust. 12 In brief, the samples were mixed with TBA solution (15% trichloroacetic acid [TCA], 0.8% TBA, 0.25 N HCl). This suspension was incubated at 951C for 15 minutes to form a pink-colored adduct, TBA-MDA adduct. The mixture was then centrifuged at 3000 rpm for 10 minutes and cooled in ice for 5 minutes. Absorption of supernatants was read at a wavelength of 532 nm. Concentrations were estimated from a standard curve of malondialdehyde bis-(dimethyl acetal) and reported as nmol MDA/mg protein.
Measurement of CAT Activity
CAT activity was determined by the method of Aebi based on the decomposition of H 2 O 2 . 13 Plasma was added to a reaction mixture containing 0.1 M potassium phosphate buffer (pH 7) and 0.05 mM H 2 O 2 . The conversion of H 2 O 2 into H 2 O and O 2 in 1 minute under standard condition was considered to be the enzyme reaction velocity. CAT activity was calculated based on an extinction coefficient of 43.1 M-1 cm-1 for H 2 O 2 at 240 nm and expressed as nmols of H 2 O 2 consumed/min/mg of protein.
Measurement of SOD Activity
SOD activity was assayed in terms of its ability to inhibit the photochemical reduction of nitroblue tetrazolium (NBT) according to Beauchamp and Fridovich. 14 The reaction mixture contained, 0.1 M potassium phosphate buffer (pH 7.4), 0.26 mM riboflavin, 2.69 mM methionine, and 2.64 mM NBT, with suitably diluted plasma in a total volume of 1.5 mL. The assay mixture was illuminated for 20 minutes by a 20 W fluorescent lamp, in aluminum foillined container. Illumination of riboflavin in the presence of O 2 and electron donor such as methionine generates superoxide anions. The reduction of NBT by superoxide radicals to blue-colored formazan was followed at 580 nm. Control without the enzyme source was always included. One unit of SOD activity is defined as that amount of enzyme that inhibits the rate of NBT reduction by 50% under the specified conditions. SOD activity was expressed as mUI/mg of protein.
Measurement of Reduced Glutathione (GSH)
Plasma GSH levels were measured as described by Weckbecker and Cory. 15 The method involved oxidation of GSH by the sulfhydryl reagent 5,5
0 -dithio-bis(2-nitrobenzoic acid) (DTNB) to form the yellow derivative 5 0 -thio-2-nitrobenzoic acid, measurable at 412 nm. In brief, plasma was diluted (1:1) in 4% sulfosalicylic acid and centrifuged at 3500 rpm for 10 minutes. The supernatant was mixed with 0.1 M potassium phosphate buffer (pH 7.4), and then with 10 mM DTNB. Le mixture was incubated for 15 minutes in the dark at room temperature. The amount of GSH in plasma was expressed as nmols/mg of protein, determined from a standard curve constructed with known concentrations of GSH.
Measurement of GPx Activity
The activity of GPx was quantified by the procedure of Flohe´and Gu¨nzler. 16 In brief, the plasma was added to a reaction mixture containing 0.1 M potassium phosphate buffer (pH 7.4) and 4 mM GSH. After 10 minutes incubation at 371C, 5 mM H 2 O 2 was added in the mixture. The reaction was then stopped by the addition of 5% TCA. After centrifugation at 3000 rpm for 10 minutes at 41C, the supernatant was combined with phosphate buffer and 10 mM DTNB and absorbance was read at 412 nm. The activity of GPx was expressed as nmol of GSH consumed/ min/mg protein.
Measurement of AOPP Levels
Levels of AOPP were determined according to the method of Kayali et al. 17 In brief, plasma was treated with phosphate buffer (0.1 M; pH 7.4). After 2 minutes incubation, 1.16 M potassium iodide and 10% TCA were added to the mixture. The concentration of AOPP for each sample was calculated based on an extinction coefficient of 261 cm-1 mM-1 at 340 nm and expressed as nmol/mg of protein.
Statistical Analysis
Statistical analysis was carried out by analysis of variance (1-way analysis of variance) followed by a Tukey test or Kruskal-Wallis/Dunn Multiple comparison test for comparison of the means, using SPSS version 20. Values for means ± SD were used. Kaplan-Meier survival curves were also performed. For all comparisons, differences were considered statistically significant at P < 0.05.
RESULTS
Patient's Characteristics
The mean age for ALL patients was 13.7 ± 8.7 years (age range, 3 mo to 29 y) and for healthy individuals was 18.3 ± 6.1 years (age range, 15 to 29 y) (P = 0.09). B-cell ALL was diagnosed for 23 patients (65.7%) and T-cell ALL for 12 patients (34.3%).
Biological characteristics of the 34 ALL patients at diagnosis and after undergoing intensive chemotherapy were summarized in Table 1 . We observed the presence of blast cells in the patients newly diagnosed. The lower White blood cell count was observed in the induction phase. Hemoglobin, mean corpuscular volume, and platelet count were decreased at diagnosis and in the induction phase and then increased in later phases.
Antioxidant Defense Levels Fig. 1 shows that the CAT and SOD activities and GSH levels were increased significantly in ALL patients, as compared with sex-matched controls (P < 0.05). We can also observe in this figure that GPx activity was decreased significantly in ALL patients, as compared with agematched controls (P < 0.05).
Post-hoc comparisons by the Tukey test revealed that GPx activity and GSH levels were significantly higher in the consolidation phase when compared with the maintenance phase (7.92 ± 1.25 vs. 6.05 ± 1.21 nmols of H 2 O 2 consumed/min/mg of protein, and 0.07 ± 0.01 vs. 0.04 ± 0.01 nmol of GSH consumed/min/mg of protein, respectively). Figure 2 shows that the plasma MDA and AOPP levels were increased significantly in ALL patients, as compared with sex-matched controls (P < 0.05).
Plasma Oxidant Levels
Post-hoc comparisons by Tukey test revealed that MDA levels were significantly higher in the induction phase when compared with the maintenance phase (0.55 ± 0.30 nmol MDA/mg of protein vs. 0.28 ± 0.12 nmol MDA/mg of protein, respectively). AOPP levels were significantly lower in the interval therapy than in the induction and consolidation phases (0.16 ± 0.05 nmol/mg of protein vs. 0.20 ± 0.03 nmol/mg of protein and 0.22 ± 0.04 nmol OPP/mg of protein, respectively).
Nine patients (26.4%) relapsed after a median duration of 380 days. We observed, using Kaplan-Meier Analysis, that the highest GSH values and SOD activity were correlated with relapse occurring in ALL patients (Fig. 3) .
DISCUSSION
This study was performed to evaluate the oxidative status and antioxidant defense in patients with ALL and its involvement in leukemic relapse.
We showed significant alterations of the antioxidant defense and increases in the production of oxygen reactive species in patients with ALL as compared with healthy individuals. This finding supports the hypothesis that cancer or malignant cells produce large numbers of ROS and that there exists a relationship between ROS activity and malignancy. 18, 19 Present observations are in agreement with other reports on various human cancers including hematological malignancies. [20] [21] [22] [23] However, there is some controversy regarding the role of oxidative stress in the development of leukemia cancer and chemotherapeutic drugs that exert their biological activity through the induction of oxidative stress in affected cells. 7 In this context, the activities of antioxidant enzymes (SOD, CAT, GPx) as well as thiol (GSH), MDA, and AOPP levels were measured before chemotherapy and during the different stages of treatment.
In the present study, MDA levels, which have been applied as biomarkers of lipid peroxidation, were shown to be increased significantly in ALL patients before or under chemotherapy when compared with the control group. These results are in accordance with the increase in TBA reactive substances levels in the serum of patients with chronic leukemia 24 and ALL. 9, 25 In addition, AOPP levels, which reflected an excess of free radical generation and protein oxidative damages, have been found to be higher in ALL patients compared with the control group.
In contrast, the levels of MDA were more increased in induction and consolidation phases than in the interval therapy. Similarly, AOPP levels increased in the induction phase then decreased progressively to achieve the lowest values in the maintenance phase. We can suggest that the increase of oxidative lesions may involve both the pathogenesis of leukemia and the toxicity of chemotherapeutic agents. The current cytotoxic drugs used in standard leukemia therapy are designed to attack the DNA replication process within malignant cells, and it does not discriminate between malignant and nonmalignant cells as it targets cell proliferation. 26 0 FIGURE 1. Antioxidant enzymatic and nonenzymatic defenses in acute lymphoblastic leukemia (ALL) patients compared with sexmatched controls. Each column represents mean ± SD. BT indicates before treatment; CAT, catalase; CP, consolidation phase; GPx, glutathione peroxidase; GSH, reduced glutathione; IP, induction phase; ITP, interval phase; MP, maintenance phase; SOD, superoxide dismutase.*,yP < 0.05, statistically significant differences, control versus ALL patients (*) or patients under therapy versus patients without therapy (y). 
Survival time Test (Days)
GSH >=3nomol/mg of protein GSH <3 nomol/mg of protein log-Rank Test, p=0.04 FIGURE 3. Relapse-free survival curves for acute leukemic patients using Kaplan-Meier analysis. AOPP indicates advanced oxidation of protein products; CAT, catalase; GPx, glutathione peroxidase; GSH, reduced glutathione; MDA, malondialdehyde; SOD, superoxide dismutase.
leukemia was accompanied by a decrease in the serum level of SOD. SOD can protect cells from low levels of oxidative stress, catalyzing the dismutation of superoxide anion produced in the cell, whereas at high levels, this enzyme acts as a peroxidase having a harmful action in the cell through the increment in hydrogen peroxide production. 28 Hydrogen peroxide, in the presence of iron or copper, has been demonstrated to be more toxic than superoxide anion due to the formation of hydroxyl radical, through the FentonHaber Weiss reaction, one of the most cytotoxic reactive oxygen species in vivo. 29 In this study, an increase in CAT activity was demonstrated in ALL patients when compared with the control group. These results contradictory to those reported by Battisti et al, 9 which show a reduced of CAT activity in ALL patients who were newly diagnosed when compared with controls. These findings suggest that there are alterations in the enzymatic antioxidant defenses, which can interfere in the direct removal of free radicals (prooxidants) and in the protection for biological sites.
Lower GPx activity was observed in ALL patients as compared with controls, similar to that reported to occur in acute lymphoblastic leukemia by others. 30, 31 GPx, an enzyme involved in the inactivation of peroxides, catalyzes the oxidation of GSH to glutathione disulfide, under oxidative stress conditions. The decrease in the activity of this antioxidant enzyme observed in ALL patients can lead to the increase in the H 2 O 2 , plasma levels and other peroxides and, consequently, to oxidative stress. 31 We also observed higher levels of GSH in ALL patients as compared with control individuals. This nonenzymatic antioxidant was correlated with the relapse of ALL patients, like SOD activity. This result is in agreement with those reported by Sarmento-Ribeiro et al, 31 in 2012, which show a correlation of GSH with the relapse and survival of ALL patients. It has been reported the increase in GSH levels was associated with drug resistance in tumor cells. 29, 32 The increase in GSH leads to increased cell survival, even in the presence of chemotherapeutic agents and, consequently, to chemotherapeutic drugs resistance and disease relapse.
Another important aspect to be discussed is that no significant correlation was observed between levels of oxidative damage (MDA or AOPP) and the risk relapse of ALL. We suggest that these findings may be a consequence of the small number of ALL patients included in this study. More studies are necessary to confirm the correlation between oxidative status and the relapse and survival of ALL patients.
In conclusion, this research provides additional contribution in the study of the oxidative profile in children newly diagnosed with ALL as compared with those in different stages of treatment. We suggest that the GSH level with SOD activity may be a significant relapse predictor in ALL patients. Therefore, it is imperative to develop new therapeutic strategies to selectively kill leukemic cells and circumvent chemoresistance by modulating oxidative stress. The application of antioxidant principles may elicit the same effect, for example, inhibition of intracellular antioxidants such as GSH proposed by Townsend et al. 33 
